DNA polymerase β (polβ) is a major contributor to mammalian DNA damage repair through its gap-filling DNA synthesis and 5 / -deoxyribose phosphate lyase activities. In this way, polβ plays pivotal roles in the repair of oxidative DNA damage, replication, embryonic survival, neuronal development, meiosis, apoptosis and telomere function. 
Introduction
DNA polymerase β (pol β) is a major contributor to the repair of DNA damage via singlenucleotide gap-filling DNA synthesis in the mammalian short-patch base-excision repair (BER) pathway (1, 2) . Polβ has been shown to play a pivotal role in repairing oxidative damage in DNA (3) (4) (5) and Sobol et al (6) reported that BER activity was defective in a mouse embryonic fibroblast (MEF) cell line derived from a polβ−knockout mouse. A DNA repair function for the 39-kDa polβ enzyme is consistent with its domain structure. An 8-kDa N-terminal domain has 5 / -deoxyribose phosphate lyase and single-strand DNA-binding activities and a 31-kDa C-terminal domain has catalytic activity (1, (7) (8) (9) . Following from its repair function, polβ plays key roles in a number of cellular processes such as DNA replication, embryonic survival, neuronal development, meiosis, apoptosis, maintenance of chromosomal integrity and establishment of drug-resistant phenotype (10) (11) (12) (13) (14) (15) . In addition, interaction between polβ and TRF2 has been shown to cause telomere dysfunction (16) . Additionally, a high mutation frequency with lower fidelity of DNA synthesis has been reported (17) , mediated by a variant of the polβ gene expressed in a colorectal adenocarcinoma (18) .
We identified a specific 87-bp deletion encoding amino acid residues 208-236 in the polβ cDNA in primary human colorectal, breast, and lung tumors and in a primary culture of renal cell carcinoma, RCC (18, (19) (20) (21) (22) . Both wild-type (WT) polβ protein and the mutant polβ protein (polβ•) lacking 29 amino acids within the catalytic domain were expressed in colorectal and breast tumors and RCC (20, 22, 23) . Other polβ variants have been shown to be expressed in prostate, bladder and gastric adenocarcinomas (19, (24) (25) (26) . Mutations in the polβ genomic sequence have also been reported in the early stages of serous ovarian cancer (27) . Taken together with the known DNA repair function of polβ, the observation of polβ variants in tumors strongly suggests that polβ plays an important role in determining susceptibility to neoplasia.
Further results suggest that polβ• inhibits functions of the WTpolβ protein in a dominant negative manner (23, 28) . Interestingly, a binary protein-protein complex of polβ• and X-ray cross complementing group I (XRCC1), a nuclear BER protein mediates such dominant-negative activity (29). The survival and growth of cells expressing polβ• were markedly reduced upon exposure to Nmethyl-N-nitro-N-nitrosoguanidine (MMNG) and N-methyl-N-nitrosourea (MNU), two known DNA alkylating agents compared with cells expressing WTpolβ protein (23, 28, 30) . These results suggest that the expression of polβ•, a dominant-negative mutant may contribute to hypersensitivity of these cells to MNNG or MNU.
We hypothesize that cells expressing polβ• protein will display diminished DNA repair activity.
Consequently, due to the persistence of lesions in DNA, error-prone replication will occur that may initiate a chain of events leading to expression of a tumorigenic phenotype. To test this hypothesis we took two approaches. First, we examined survival, morphological transformation, gap-filling DNA synthesis activity of MNU-treated cells expressing polβ• in the absence of WTpolβ. The ability of these cells to form tumors in nude mice was also investigated. In a second approach, we established a transgenic mouse line expressing the polβ• specifically in the mammary glands. In this model, endogenous WTpolβ was expressed in the same cells as the transgene-encoded polβ• protein, allowing the dominant-negative function of polβ• to be expressed. Tumor formation in transgenic and control mice treated with MNU was evaluated. The data from both of these experimental approaches provide evidence that polβ• expression potentiates MNU-induced cellular transformation and tumor formation. Moreover, the increased susceptibility of polβ• transgenic mice to MNUinduced mammary carcinogenesis supports a dominant-negative role for the polβ• mutant.
Materials and methods

Cell lines
The stable mouse embryonic fibroblast (MEF) 19.4•P cell line was established in this laboratory by transfecting 19.4 MEF derived from a polβ knockout mouse (9) with a polβ• 208-236 plasmid (23).
G418-resistant colonies were selected by growth in DMEM-glutamex. The 19.4•P cells were grown in DMEM supplemented with 80µg/ml hygromycin, 700 µg/ml G418, 10% FBS and penicillin and streptomycin. To obtain average activity, a pooled cell line named 19.4•P was made by mixing an equal number of cells from 30 individual expanded colonies. The 16.3 MEF cell line (9) expressing WT polβ was used as a control (23, 29) .
Western blot analysis
To determine expression of polβ in cells or tumor tissues, cell extracts were prepared (23) and separated by 12% SDS-PAGE. The proteins were transferred to membrane and detected by a purified anti-polβ antibody.
Gap-filling synthesis activity assay
The gap-filling DNA synthesis activity in nuclear extracts was determined essentially as described in (23, 28) . A 51-bp double-stranded DNA with a G :U mismatch at position 22 was used as the substrate. The reaction mixture consisted of 10 units creatine phosphokinase, 2 µg BSA, 500 mM HEPES, pH 7.9, 100 mM MgCl 2 , 600 mM KCl, 20 mM DTT, nuclear extract and 32 P-dCTP (3000 Ci/mmol) in a volume of 50 µl. It was incubated at 37 0 C for 30 min and cooled on ice to terminate the reaction. The product was separated by 6% PAGE and the radioactivity was detected on the Xray film at -80 0 C.
Cell survival assay
A colony-forming assay (23) 
Morphological transformation assay
Two thousands cells were treated with MNU at various doses for 1 hour (31, 32) . Cells were also incubated in the medium containing DMSO (final concentration: 0.005%), which served as a solvent control. The MNU/DMSO was removed through multiple washings with PBS and cells were allowed to grow for 6 weeks with a change of medium twice a weekly. Transformed colonies were then fixed with 70% methanol, stained with Giemsa and scored as either types II or III (31, 32) . The foci index was calculated as the number of foci per dish. For transfer into nude mice (see below), Type III foci were isolated from unstained dishes using cloning cylinders.
.
Tumorigenic potential of transformed cells
Type III transformed cells were grown in mass culture for three passages. To determine whether growth was anchorage-independent or dependent in soft agar, cells were seeded in 0.33% agar on a 5% agar base layer (31, 32) . Untreated cells were used as a control. Colonies of transformed cells that formed in the soft agar layer were isolated using Pasteur pipettes and grown in mass culture. 5 X 6 cells from these cultures were suspended in PBS were injected subcutaneously into the backs of male athymic Nu/Nu mice (32) . Animals were examined for tumor appearance every third day.
Resulting tumors were excised, fixed in 4% formalin, paraffin blocked and stained with hematoxylene and eosin for histopathological evaluation. Injected mice were observed closely for body weight loss, abnormal behavior such as poor physical activity, heavy breathing, poor eating or drinking, serious scratching or for any signs of pain. Mice approaching one of these states were humanely euthanized in a CO 2 chamber.
Construction of the polβ• transgene
To establish a transgenic human polβ• mouse line, we generated a 2.9-kb transgene construct consisting of a 5' whey acidic protein (WAP) promoter followed by the polβ and HindIII/polβ reverce (5'-ATACCCAAGCTTTCATTCGCTCCGGTCCTTGG-3') primers. The PCR-amplified product was cloned into a pBluescript vector that has WAP 3' sequence at SpeIHindIII sites. The polβ• and +WAP 3' sequence was further amplified from the resulting plasmid pPolβ•/WAP 3' using the forward primer (as above) and a polβ reverse primer containing a SacII cleavage site at the 3' end (5'-ATATCCCCGCGGTATAGGGCGAATTGGGTACC-3'). The amplified product was then cloned into the SpeI-SacII sites of the plasmid pBL103, 3' to the WAP 5'
sequence. The orientation of the Polβ•/WAP insert and the cloning junctions were confirmed by sequencing. The transgene was excised from the plasmid for microinjection using BssHII.
Microinjection and generation of transgenic mice
The purified 2.9-kb WAP-polβ• construct was microinjected into pronuclei of B6CBA mice by our Transgenic Core Facility. Sixteen pups were born. Tail clips were taken from the pups at 7-10 days of age. DNA was isolated from the tail clips and analyzed by PCR and Southern blot for the presence of the transgene.
DNA-PCR
DNA was initially characterized by PCR using a WAP+1 forward (5'-ATCAGTCATCACTTG CCTGCCGCCG-3') and a polβ reverse primer (5'-TTCTTCTCAAAGTTTGCGAG-3').
Southern blot assay
DNA samples from all 16 mice were digested with SpeI and HindIII and analyzed by Southern blot using a ~960-bp SpeI+HindIII-digested polβ• cDNA transgene probe. The probe was labeled with α- All studies involving mice were performed in accordance with NIH and AAALAC guidelines for the humane care and use of research animals.
Results
Characterization of polβ knockout MEFs with stable expression of the polβ• mutant
In order to examine the biological relevancy of the expression of polβ To characterize the activity of the polβ mutant expressed in the 19.4•P cells, DNA repair activity was measured in nuclear extracts using gap-filling DNA synthesis assay. The repair activity was reduced substantially in the 19.4•P cells (Fig.1B, lane 2) as compared to the 16.3 cells (Fig.1B, lane 3) . These results indicate that the deletion of 29 amino acid residues in the catalytic domain of polβ results in an enzyme (polβ•) that has impaired DNA repair capability.
Expression of polβ• adversely affects survival of MEFs exposed to the mutagen, MNU
To To test polβ function, we measured gap-filling DNA synthesis activity in nuclear extracts from the 19.4•P#53 cell lines and tumor #29. Nuclear extracts from 16.3 cells were used as a positive control. A 51-bp repaired product was identified in all tested nuclear extracts (Fig.4, panel B) . The intensity of the repaired product in tumor #29 was comparable to that generated by the 16.3 nuclear extract. This result suggests that the endogenou WTpolβ protein expressed in tumor#29 provides sufficient catalytic activity to generate normal levels of DNA repair activity. In contrast, decreased gap-filling DNA synthesis activity was observed in the 19.4•P and19.4•P#53 nuclear extracts. This is expected since these cells express only the mutant polβ protein that has a deletion of 29 amino acid residues within the catalytic domain. Since we reported previously that MCF-7 breast cancer cells expressing 39-kDa WT polβ protein exhibit efficient repair activity (34), we used a nuclear extract from MCF-7 cells as an additional control in this experiment.
The data indicate that polβ-mediated DNA repair is deficient in 19. 
Generation of transgenic mice expressing mutant polβ in the mammary glands
To direct expression of polβ• in transgenic mice, we chose the whey acidic protein (WAP) promoter (35) (36) (37) . The advantage of using the WAP promoter is that it is highly expressed in the mammary glands of pregnant mice (35) (36) (37) . Our strategy was to establish transgenic mice expressing both endogenous polβ and polβ• that would mimic expression of polβ identified in human tumors (18) (19) (20) (21) (22) (23) . The transgenic construct is illustrated in Fig. 5A . Digestion of the plasmid polβ•/WAP3 / /WAP5 / by BssHII separated the 2.9-kb transgene from the 3-kb vector (Fig.5B) prior to microinjection. Sixteen founder pups were born and DNA prepared from tail clips was analyzed for the presence of the transgene using DNA-PCR with a WAP+1
forward primer and a polβ reverse primer. A 245-bp PCR product of the expected size was identified in two founder mice (Fig.5C, lanes 4 and 5) . The PCR product was not detected in the remaining 14 animals (represented by two mice, lanes 2 and 3) indicating that the transgene was not transmitted to the DNA of these animals. DNA samples from all 16 mice were further analyzed by Southern blot by digestion with
SpeI and HindIII and hybridization to a ~960-bp SpeI and HindIII digested polβ• cDNA probe. Fig.5D shows a hybridizing fragment of ~960-bp in two transgenic mice showing in lanes 5 and 6 (shown by an arrow). DNA samples shown in lanes 4 and 5 (PCR) and lanes 5 and 6 (Southern) were from same positive mice, respectively. These results confirm that the polβ• transgene was transmitted to two founder mice while the other 14 animals were nontransgenic. The Southern blot also shows fragments larger than 2-kb that hybridized to the transgene probe. These fragments might be due to incomplete digestion of the genomic DNA. Lane 8 shows the ~960-bp probe used as a marker.
Balb/c mice have been reported to be susceptible to MNU-induced mammary tumorigenesis (38, 39) .
Hence, the two positive founder animals were mated with normal Balb/c mice to establish a transgenic mouse line. Eighteen pups were born from these matings. Tail DNA from the F1 pups was examined by Southern blot to confirm that the transgene had been transmitted. As shown in Fig. 5E To evaluate whether the WAP-polβ• transgene was expressed in the mammary glands of transgenic mice, cell extracts were made from the mammary glands of two F1 mice (#1 and #2), 1-week after delivery of littermates as WAP is expressed when prolactin and progesterone are at high levels in serum. 
Mammary carcinogenesis in transgenic mice expressing the polβ deletion mutant
In order to examine tumorigenesis in transgenic mice expressing polβ• in the mammary glands, we first established the LD 50 of MNU in these mice. Transgenic animals were given MNU at a dose of 25 to 200 mg/kg body weight intraperitoneally once a week for 3 weeks (at 7 and 14 days of pregnancy and 1 week after litters were born). MNU at a dose of 100 mg/kg body weight was found to be lethal, establishing 50mg/kg body weight as the LD 50 (data not shown).
To compare the susceptibility of transgenic and wild-type mice to MNU-induced tumorigenesis, pregnant female transgenic OCF6 generation (~98% Balb/c background) and normal pregnant female Balb/c mice (of similar age and genetic background as transgenic animals) were treated on identical schedules with MNU at 50mg/kg body weight. Intraperitoneal injections were given for 7 weeks, starting at day 7 of pregnancy and continuing to the fourth week of the lactation period. Pups were kept with their mothers so that nursing would maintain high levels of prolactin in the serum important for expression of the WAPdriven polβ• transgene. Mammary tumors were identified by palpation and were first detected in MNUtreated transgenic mice at 12 weeks after MNU injection. In contrast, tumors did not appear in similarly treated control mice until 28 weeks (Fig.7A) . Thus transgene expression is correlated with an earlier appearance of MNU-induced mammary tumors.
Moreover, the percentage of transgenic mice that developed MNU-induced mammary tumors (70%) was significantly higher than for control mice (22%) (Fig.7B) . Mammary tumors were identified at both upper right and left sides of upper and lower body of trnasgenic mice treated with MNU. All mammary tumors were identified by the Mouse Phenotyping Service, Ohio State University, Columbus, OH as adenosquamous carcinomas (Fig.8, lower panel) . The histology of a normal mammary gland from an untreated Balb/c mouse is shown in Fig.8 expression is controlled by the strong mammalian tissue-specific promoter, the WAP promoter (35) (36) (37) . The construct also uses an 843-bp of 3' WAP sequence that contains a 70-bp untranslated region including a poly A region. These sequences have been shown to determine tissue-specificity and integration site, independent of transgene expression (35, 42) . The advantage of using the WAP promoter for our study is that it is highly expressed in mammary glands of pregnant transgenic mice (35) (36) (37) . The prolactin hormone secreted during pregnancy stimulates the ovaries to secrete progesterone and estradiol. This combination of hormones in pregnant mice causes proliferation of mammary epithelial cells that enhances chemical-or oncogene-mediated mammary tumorigenesis (35) (36) (37) 39, 42) . In addition, a number of transgene constructs driven by the WAP promoter have been successfully used to study mammary carcinogenesis (36, 37) . The data presented in this study demonstrates that the polβ• transgene was effectively expressed in the target organ of the WAPdriven polβ• transgene, the mammary glands. Since the transgenic mice express endogenous WTpolβ in addition to the transgene-encoded mutant polβ, this transgenic model mimics the observed expression of polβ (WT and mutant) in many human tumors when normal control mouse expressing WTpolβ mimics normal matched tissues (20, 22, 23) . Our analysis of control and transgenic pregnant mice exposed to MNU showed that transgene expression resulted in a higher incidence of tumor formation, with tumor forming in multiple mammary glands of each animal. Furthermore, the latent period prior to tumor appearance was significantly shorter in transgenic animals than in control mice.. 
